Stella Pharma Concludes MOU on Boron Neutron Capture Therapy System with Fujita Health University, Atransen Pharma, SHI, and Fujita

Stella Pharma Corporation has concluded a Memorandum of Understanding (MOU) to promote research and development of deep-seated tumor treatment using the Boron Neutron Capture Therapy System (BNCT) with Fujita Health University, Atransen Pharma Co., Ltd., Sumitomo Heavy Industries, Ltd. (SHI), and Fujita Corporation.

1．Purpose
BNCT has previously been restricted in treatment of tumors to a maximum depth of 6–8 cm from the body surface where neutrons can be safely and effectively delivered. The aim of the MOU is to contribute to the further development of treatment for deeper-seated tumors by sharing expertise and knowledge of the five parties (see table below) and solving this issue of BNCT. Research and development will explore new possibilities of cancer treatment.

２．Role of each party
Each party will promote research and development toward joint implementation of clinical trials, aiming to adapt BNCT to deeper-seated tumors.

Role of each party

We will continue our efforts to provide BNCT as new cancer treatment option as soon as possible.